Literature DB >> 16388798

Changes in pH differently affect the binding properties of histamine H1 receptor antagonists.

Michel Gillard1, Pierre Chatelain.   

Abstract

We investigated the effect of acidic pH, a condition that can be encountered during inflammation accompanying allergic reaction, on the binding properties of histamine H1 receptor antagonists, including levocetirizine ((2-(4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl)ethoxy)acetic acid; Xyzal ), fexofenadine (rac-2-[4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl) piperidin-1-yl]butyl]phenyl]-2-methylpropionic acid hydrochloride; Allegra) and desloratadine (8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Clarinex ). Lowering the pH from 7.4 to 5.8 decreased the affinity of [3H]mepyramine for histamine H1 receptors from 1.7 to 7.5 nM while the opposite was observed with [3H]levocetirizine, whose affinity increased from 4.1 to 1.5 nM. Competition curves with [3H]mepyramine indicated that decreasing the pH from 7.4 to 5.8 led to a 2- to 5-fold increase in the affinity of fexofenadine and levocetirizine, no change in affinity for desloratadine and a 5- to 10-fold decrease in affinity for mepyramine and histamine. Kinetic experiments showed that the increase in affinity of levocetirizine and, to a lesser extent, fexofenadine were totally attributable to a lower dissociation rate at acidic pH (t1/2 increasing from 77 to 266 min and from 71 to 135 min, respectively). Although the affinity of desloratadine remained unchanged, lowering the pH caused a decrease in its dissociation rate (t1/2 of 50 and 256 min at pH 7.5 and 5.8, respectively) accompanied by a concomitant 3.5-fold decrease in its association rate constant. The loss of affinity of mepyramine at acidic pH was driven by a decrease in its association rate constant. Interaction between the carboxylic moiety of levocetirizine and Lys191 is responsible for its slow dissociation rate from the receptor. We found that the magnitude of the pH effect on the dissociation rate of levocetirizine was maintained after mutating Lys191 into alanine, suggesting that a tighter interaction of levocetirizine with Lys191 at lower pH is not the cause of its even slower dissociation rate from the receptor. Although these changes may seem limited in amplitude, we show that they may have substantial effects on receptor occupancy in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16388798     DOI: 10.1016/j.ejphar.2005.11.051

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Selective Aryl Hydrocarbon Receptor Modulator 3,3'-Diindolylmethane Impairs AhR and ARNT Signaling and Protects Mouse Neuronal Cells Against Hypoxia.

Authors:  J Rzemieniec; E Litwa; A Wnuk; W Lason; W Krzeptowski; M Kajta
Journal:  Mol Neurobiol       Date:  2015-10-17       Impact factor: 5.590

2.  Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H(1) and H(3) receptors.

Authors:  R J Slack; L J Russell; D A Hall; M A Luttmann; A J Ford; K A Saunders; S T Hodgson; H E Connor; C Browning; K L Clark
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 3.  Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies.

Authors:  Philip I Hair; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Histamine/H1 receptor signaling in the parafacial region increases activity of chemosensitive neurons and respiratory activity in rats.

Authors:  C R Sobrinho; B M Milla; J Soto-Perez; T S Moreira; D K Mulkey
Journal:  J Neurophysiol       Date:  2022-06-15       Impact factor: 2.974

Review 5.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

Review 6.  Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Authors:  Philippe Devillier; Nicolas Roche; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Exploring the Effect of Cyclization of Histamine H1 Receptor Antagonists on Ligand Binding Kinetics.

Authors:  Zhiyong Wang; Reggie Bosma; Sebastiaan Kuhne; Jelle van den Bor; Wrej Garabitian; Henry F Vischer; Maikel Wijtmans; Rob Leurs; Iwan J P de Esch
Journal:  ACS Omega       Date:  2021-05-07

8.  Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria.

Authors:  E Nettis; G F Calogiuri; E Di Leo; F Cardinale; L Macchia; A Ferrannini; A Vacca
Journal:  J Asthma Allergy       Date:  2008-12-16

9.  The Target Residence Time of Antihistamines Determines Their Antagonism of the G Protein-Coupled Histamine H1 Receptor.

Authors:  Reggie Bosma; Gesa Witt; Lea A I Vaas; Ivana Josimovic; Philip Gribbon; Henry F Vischer; Sheraz Gul; Rob Leurs
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

10.  Pharmacology of antihistamines.

Authors:  Diana S Church; Martin K Church
Journal:  World Allergy Organ J       Date:  2011-03       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.